Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine

1 Jan 2019

Abstract excerpt

Nine per cent of patients with metastatic cancer harbour genomic alterations that are recognised as biomarkers for optimal treatment selection in current standard of care. An additional 27% carries genomic aberrations for which compelling clinical evidence exists supporting the use of these alterations as predictive biomarkers for drug response outside the registered indication.1 As novel molecular and genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31233036
DOI: 10.1136/esmoopen-2019-000516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancing molecular tumour boards: highly needed to maximise the impact of precision medicinePMID 31233036Read ↗

The molecular tumor board—a key element of precision oncologySemantic proximity Read ↗

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.Semantic proximity Read ↗

Molecular Tumor Boards: Realizing Precision Oncology Therapy.Semantic proximity Read ↗

Advances in Personalized OncologySemantic proximity Read ↗

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.Semantic proximity Read ↗

Precision oncology: separating the wheat from the chaffSemantic proximity Read ↗

Molecular Tumor Board: The University of California San Diego Moores Cancer Center ExperienceSemantic proximity Read ↗

Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical TrialsSemantic proximity Read ↗

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read ↗

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceSemantic proximity Read ↗

Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience.Semantic proximity Read ↗

Molecular pathology of cancer: how to communicate with diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.